Stocks
Corcept Therapeutics Incorporated Financial Statements (CORT) |
||||||||||
| Corcept Therapeutics Incorporatedsmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 24.02.2020 | 23.02.2021 | 15.02.2022 | 28.02.2023 | 15.02.2024 | 01.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 306.5 | 353.9 | 366.0 | 401.9 | 482.4 | 523.5 | |||
| Operating Income, bln rub | 111.6 | 128.2 | 124.5 | 112.6 | 107.3 | 121.9 | ||||
| EBITDA, bln rub | ? | 111.6 | 128.2 | 124.5 | 112.6 | 109.6 | 123.7 | |||
| Net profit, bln rub | ? | 94.2 | 106.0 | 112.5 | 101.4 | 106.1 | 118.0 | |||
| OCF, bln rub | ? | 136.1 | 152.0 | 167.9 | 120.3 | 127.0 | 124.8 | |||
| CAPEX, bln rub | ? | 1.09 | 1.24 | 0.469 | 0.413 | 0.139 | 0.139 | |||
| FCF, bln rub | ? | 135.0 | 150.7 | 167.4 | 119.9 | 126.9 | 124.7 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 189.4 | 220.1 | 236.2 | 283.8 | 368.6 | 394.0 | ||||
| Cost of production, bln rub | 5.50 | 5.58 | 5.28 | 5.39 | 6.48 | 7.63 | ||||
| R&D, bln rub | 89.0 | 114.8 | 113.9 | 131.0 | 184.4 | 202.0 | ||||
| Interest expenses, bln rub | 5.07 | 0.000 | 0.000 | 3.56 | 0.000 | 3.58 | ||||
| Assets, bln rub | 412.3 | 571.7 | 423.8 | 583.4 | 621.5 | 655.9 | ||||
| Net Assets, bln rub | ? | 371.2 | 523.3 | 375.8 | 501.8 | 506.7 | 547.9 | |||
| Debt, bln rub | 3.46 | 2.55 | 0.526 | 1.14 | 0.151 | 0.076 | ||||
| Cash, bln rub | 315.3 | 476.9 | 335.8 | 436.6 | 368.2 | 410.8 | ||||
| Net debt, bln rub | -311.9 | -474.3 | -335.3 | -435.5 | -368.1 | -410.7 | ||||
| Ordinary share price, rub | 12.1 | 26.2 | 19.8 | 20.3 | 32.5 | 25.3 | ||||
| Number of ordinary shares, mln | 114.3 | 115.4 | 115.7 | 106.8 | 103.6 | 102.8 | ||||
| Market cap, bln rub | 1 384 | 3 019 | 2 290 | 2 169 | 3 364 | 2 600 | ||||
| EV, bln rub | ? | 1 072 | 2 545 | 1 955 | 1 733 | 2 996 | 2 189 | |||
| Book value, bln rub | 371 | 523 | 376 | 502 | 507 | 548 | ||||
| EPS, rub | ? | 0.82 | 0.92 | 0.97 | 0.95 | 1.02 | 1.15 | |||
| FCF/share, rub | 1.18 | 1.31 | 1.45 | 1.12 | 1.23 | 1.21 | ||||
| BV/share, rub | 3.25 | 4.53 | 3.25 | 4.70 | 4.89 | 5.33 | ||||
| EBITDA margin, % | ? | 36.4% | 36.2% | 34.0% | 28.0% | 22.7% | 23.6% | |||
| Net margin, % | ? | 30.7% | 30.0% | 30.7% | 25.2% | 22.0% | 22.5% | |||
| FCF yield, % | ? | 9.76% | 4.99% | 7.31% | 5.53% | 3.77% | 4.80% | |||
| ROE, % | ? | 25.4% | 20.3% | 29.9% | 20.2% | 20.9% | 21.5% | |||
| ROA, % | ? | 22.8% | 18.5% | 26.6% | 17.4% | 17.1% | 18.0% | |||
| P/E | ? | 14.7 | 28.5 | 20.4 | 21.4 | 31.7 | 22.0 | |||
| P/FCF | 10.2 | 20.0 | 13.7 | 18.1 | 26.5 | 20.8 | ||||
| P/S | ? | 4.51 | 8.53 | 6.26 | 5.40 | 6.97 | 4.97 | |||
| P/BV | ? | 3.73 | 5.77 | 6.09 | 4.32 | 6.64 | 4.74 | |||
| EV/EBITDA | ? | 9.60 | 19.9 | 15.7 | 15.4 | 27.3 | 17.7 | |||
| Debt/EBITDA | -2.79 | -3.70 | -2.69 | -3.87 | -3.36 | -3.32 | ||||
| R&D/CAPEX, % | 8 182% | 9 270% | 24 278% | 31 717% | 132 628% | 145 328% | ||||
| CAPEX/Revenue, % | 0.35% | 0.35% | 0.13% | 0.10% | 0.03% | 0.03% | ||||
| Corcept Therapeutics Incorporated shareholders | ||||||||||
